• OncoGenex Pharmaceuticals Inc., of Bothell, Wash., reported preliminary results from a Phase II trial that showed 71 percent of chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with OGX-427 plus prednisone had no disease progression at 12 weeks compared with 33 percent of those treated with prednisone alone. The OGX-427 group also had greater declines in prostate-specific antigen and circulating tumor cells.